Erratum to: Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis.

Le résumé fourni par la source

[Erratum to: BMB Reports 2025; 58(3): 140-145, PMID: 39757202, PMCID: PMC11955732] The BMB Reports would like to issue a correction to an article published in BMB Rep. 58(3): 140-145, titled "Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis". The original acknowledgment contained incorrect grant information. This has now been corrected at the authors' request as follows: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2016R1 A6A3A11930589, NRF-2016R1A6A3A11934500, NRF-2016 R1D1A3 B03931646, NRF-2019R1I1A1A01057738, NRF-2019R1l1A3A01060016, NRF-2019R1l1A1A01060116, and RS-2023-00248058). It was also supported by the Chungnam National University Hospital Research Fund 2021 (2021-CF-033). Specifically, the grant number has been updated from 2016 (2016-CF-003) to 2021 (2021-CF-033). The authors apologize for any inconvenience or confusion this error may have caused. The ACKNOWLEDGEMENTS section in the original PDF version has been updated accordingly.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.